Jubilant Pharmova's ₹53.37 cr tax setback
Income tax rectification order disallows brought-forward losses at subsidiary Jubilant Biosys, but the company says it will appeal and sees no material impact.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- Jubilant Pharmova subsidiary Jubilant Biosys received a rectification order disallowing ₹53.37 cr in brought-forward losses.
- The order is dated June 29, 2026, and was received on June 30.
- Jubilant Pharmova plans to appeal before the National Faceless Appeal Centre.
Why this matters
The disallowed losses represent just 0.35% of Jubilant's ₹15,361 cr market cap, making the financial blow negligible. The company expects relief on appeal, so the risk of a permanent cash outflow is low. However, it adds to a string of recent tax and regulatory headwinds: earlier this month, a tax demand was reduced to ₹42.41 cr, and FDA actions have hit plants in Montreal and Spokane.
What we're watching
- Outcome of the appeal — if upheld, the cash impact is tiny; if not, it remains immaterial.
- Any further tax or regulatory developments, given the prior FDA warning letter in May.
- The next quarterly call for management's commentary on pending litigations.
The full read
Jubilant Pharmova's wholly-owned subsidiary Jubilant Biosys has been hit with a rectification order disallowing ₹53.37 crore in brought-forward losses for AY 2019-20, a sum that represents just 0.35% of the parent's ₹15,361 crore market cap and about 45% of its latest quarterly net profit. The order arrived June 30 from the income tax department. The company will appeal, arguing the adjustment is factually wrong. Even if the appeal fails, a loss this size would barely dent earnings. Hardly a headline. The stock's bigger overhangs remain the FDA Warning Letter at its Montreal plant and the Spokane facility's 8 observations. This tax item is a footnote.
Questions answered
- What is the exact amount disallowed and for which year?
- The income tax department disallowed brought-forward losses of ₹53.37 crore for assessment year 2019-20 for Jubilant Biosys.
- How significant is this amount relative to Jubilant Pharmova's financials?
- The ₹53.37 crore is only about 0.35% of the company's ₹15,361 crore market cap and roughly 45% of its latest quarterly net profit of ₹119 crore. But the company sees no material adverse impact and expects relief on appeal.
- What is the company's next step?
- Jubilant Pharmova will file an appeal before the National Faceless Appeal Centre, arguing the rectification ignores facts and law.
- Does this relate to any prior tax issues?
- Yes, earlier in June 2026, Jubilant Generics received a rectification reducing a tax demand to ₹42.41 crore. This new order is a separate disallowance at Jubilant Biosys.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 30 Jun 2026 · 6:48 PM IST Jubilant Pharmova's ₹53.37 cr tax setback
- 12d ago Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 17d ago Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 38d ago USFDA hits Jubilant's Montreal plant with a Warning Letter
- 45d ago Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand